CORDARONE TABLET 200 MG

Χώρα: Ινδονησία

Γλώσσα: Ινδονησιακά

Πηγή: Badan Pengawas Obat dan Makanan RI - Indonesian Food and Drug Supervisory Agency

Αρχείο Π.Χ.Π. Αρχείο Π.Χ.Π. (SPC)
24-10-2021

Δραστική ουσία:

AMIODARONE

Διαθέσιμο από:

AVENTIS PHARMA - Indonesia

INN (Διεθνής Όνομα):

AMIODARONE

Δοσολογία:

200 MG

Φαρμακοτεχνική μορφή:

TABLET

Μονάδες σε πακέτο:

DUS, 3 BLISTER @ 10 TABLET

Κατασκευάζεται από:

AVENTIS PHARMA - Indonesia

Ημερομηνία της άδειας:

2019-02-28

Αρχείο Π.Χ.Π.

                                BASED ON AMIODARONE-CCDSV12 –CCDSV19 + CCDS V20 + CCDS V21 + EU SMPC
+ REMOVE FR MAH INFORMATION
+ ADDITION OF HALAL LOGO
CORDARONE

AMIODARONE HCL
200 MG
QUALITATIVE AND QUANTITATIVE COMPOSITION:
Each tablet contains:
Amiodarone (NN) hydrochloride ……….… 200 mg
Excipient: include lactose
PHARMACEUTICAL FORM
Tablet of 200 mg Amiodarone
PHARMACOLOGICAL PROPERTIES
_ANTI ARRHYTHMIC PROPERTIES : _
-
Reduced
sinus
automaticity
leading
to
bradycardia
unresponsive
to
atropine
administration.
-
Non-competitive alpha and beta adrenergic inhibition.
-
Slowing in sino-atrial, atrial and nodal conduction, _ which is
increased in proportion to _
_rhythm rapidity _
-
No change in intra ventricular conduction.
-
Increased in refractory period and decrease of myocardial excitability
at the atrial, nodal
and ventricular levels.
-
Slowing in conduction and prolongation of refractory periods in
accessory atrioventricular
pathways.
_OTHER PROPERTIES: _
-
Moderate drop in peripheral resistance and decrease in heart rate
leading to a reduction
of oxygen intake.
-
Increase of coronary output due to a direct effect on myocardial
arteries smooth muscle.
-
Maintenance of cardiac output due to a decrease in aortic pressure and
peripheral
resistance.
OTHERS
-
No significant negative inotropic effect.
PHARMACOKINETICS PROPERTIES
Amiodarone has a slow transit and a high affinity to tissues.
Oral bioavailability has varied between 30 and 80% along with
individual patients (mean
value
around
50%).
Following
single
administration,
peak
plasma
concentrations
are
DISETUJUI OLEH BPOM: 05/10/2021
EREG100022VR12100078
BASED ON AMIODARONE-CCDSV12 –CCDSV19 + CCDS V20 + CCDS V21 + EU SMPC
+ REMOVE FR MAH INFORMATION
+ ADDITION OF HALAL LOGO
reached after 3 to 7 hours. Therapeutic effects are usually obtained
after one week (from a
few days to two weeks), according to the loading dose.
Amiodarone has a long half-life including considerable inter-patient
variability (from 20 to
100 days). During the first days of therapy, the drug accumulate
                                
                                Διαβάστε το πλήρες έγγραφο
                                
                            

Αναζήτηση ειδοποιήσεων που σχετίζονται με αυτό το προϊόν

Προβολή ιστορικού εγγράφων